Compare Novo Nordisk A/S (NVO) vs SpaceX (SPCX) Price & Performance

Novo Nordisk A/STrade

SpaceXTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs SpaceX — how do they compare? Novo Nordisk A/S trades at $45.04 (market cap $198.57B), while SpaceX trades at $146.81 (market cap $1.94T). The key difference: SpaceX is far larger — about 9.8× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.03% dividend while SpaceX pays none. Which is the better fit depends on your goals.

	NVO	SPCX
Market Cap	$198.57B	$1.94T
Sector	Health	Technology
52-Week High	$63.98	$202.09
52-Week Low	$35.29	$108.27
Enterprise Value	$213.37B	$1.88T
Dividend Yield	4.03%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.

The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.

SpaceX

SPCX trades at $153.47, up 3.73% today, with strong analyst support (90% buy ratings) and a $227.22 consensus price target suggesting 48% upside. Despite negative profitability metrics, the company shows robust revenue growth and significant cash flow generation. Technical indicators show a bullish trend with key support at $147 and resistance at $157. Recent news highlights insider share unlocks creating temporary selling pressure but strong institutional interest.

The outlook remains positive given SpaceX's innovation pipeline and market leadership, though investors face risks from high valuation multiples, ongoing losses, and competitive pressures. The stock's premium valuation requires continued execution on growth targets to justify current levels.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 2 days agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

SPCX

AI-driven IPO surge in 2026 echoes 1999 Internet Boom with high valuations despite lossesSeeking Alpha · 21 hours agoBearish SpaceX shares drop 5% as $47.2B insider share unlock hits market, dragging space sector down.24/7 Wall Street · 22 hours agoBearish Anthropic researcher warns AI has >10% chance to kill all humans within a decade amid safety concerns.CNBC · 1 day agoBearish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About SpaceX

SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.